Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2016, Article ID 2736805, 4 pages
http://dx.doi.org/10.1155/2016/2736805
Case Report

Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus

1Department of Experimental, Diagnostic and Specialty Medicine, Nephrology, Dialysis and Transplantation Unit, St. Orsola Hospital, University of Bologna, 40138 Bologna, Italy
2Clinical Microbiology Unit, St. Orsola Hospital, University of Bologna, 40138 Bologna, Italy

Received 19 November 2015; Accepted 17 January 2016

Academic Editor: Władysław Sułowicz

Copyright © 2016 Viola Menghi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Fishman, V. Emery, R. Freeman et al., “Cytomegalovirus in transplantation—challenging the status quo,” Clinical Transplantation, vol. 21, no. 2, pp. 149–158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. P. Scolari, M. L. Cappuccilli, N. Lanci et al., “Predictive factors in chronic allograft nephropathy,” Transplantation Proceedings, vol. 37, no. 6, pp. 2482–2484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. N. Kotton, D. Kumar, A. M. Caliendo et al., “International consensus guidelines on the management of cytomegalovirus in solid organ transplantation,” Transplantation, vol. 89, no. 7, pp. 779–795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. P. Limaye, “Ganciclovir-resistant cytomegalovirus in organ transplant recipients,” Clinical Infectious Diseases, vol. 35, no. 7, pp. 866–872, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Couzi, S. Helou, T. Bachelet et al., “High incidence of anticytomegalovirus drug resistance among D+R-kidney transplant recipients receiving preemptive therapy,” American Journal of Transplantation, vol. 12, no. 1, pp. 202–209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Boivin, N. Goyette, M. Farhan, J. Ives, and R. Elston, “Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis,” Journal of Clinical Virology, vol. 53, no. 3, pp. 208–213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Eid, S. K. Arthurs, P. J. Deziel, M. P. Wilhelm, and R. R. Razonable, “Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes,” Clinical Transplantation, vol. 22, no. 2, pp. 162–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Chou, “Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir,” Reviews in Medical Virology, vol. 18, no. 4, pp. 233–246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. C. N. Kotton, D. Kumar, A. M. Caliendo et al., “Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation,” Transplantation, vol. 96, no. 4, pp. 333–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Sabé, J. González-Costello, I. Rama et al., “Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors,” Transplant International, vol. 25, no. 7, pp. e78–e82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Chou, R. H. Waldemer, A. E. Senters et al., “Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir,” Journal of Infectious Diseases, vol. 185, no. 2, pp. 162–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. W. J. Chon, P. V. Kadambi, C. Xu et al., “Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago,” Case Reports in Nephrology and Dialysis, vol. 5, no. 1, pp. 96–105, 2015. View at Publisher · View at Google Scholar
  13. N. Basic-Jukic, P. Kes, L. J. Bubic-Filipi, Z. Puretic, B. Brunetta, and J. Pasini, “Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?” Transplantation Proceedings, vol. 37, no. 2, pp. 850–851, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Satoh, H. Tada, M. Murakami et al., “The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation,” Transplantation Proceedings, vol. 37, no. 4, pp. 1751–1753, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Moreso, D. Serón, J. M. Morales et al., “Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses,” Clinical Transplantation, vol. 12, no. 3, pp. 198–205, 1998. View at Google Scholar · View at Scopus
  16. C. G. Ter Meulen, J. F. M. Wetzels, and L. B. Hilbrands, “The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation,” Nephrology Dialysis Transplantation, vol. 15, no. 5, pp. 711–714, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. H.-A. Myhre, D. H. Dorenberg, K. I. Kristiansen et al., “Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients,” Transplantation, vol. 92, no. 2, pp. 217–223, 2011. View at Publisher · View at Google Scholar · View at Scopus